Optimizing Stroke and Bleeding Risk Assessment in Patients with Atrial Fibrillation: A Balance of Evidence, Practicality and Precision

Marco Proietti; Nebojsa Mujovic; Tatjana S. Potpara

doi:10.1055/s-0038-1676074

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2018; 118(12): 2014-2017
DOI: 10.1055/s-0038-1676074

Invited Editorial Focus

Georg Thieme Verlag KG Stuttgart · New York

Optimizing Stroke and Bleeding Risk Assessment in Patients with Atrial Fibrillation: A Balance of Evidence, Practicality and Precision

Marco Proietti

¹Istituto di Ricerche Farmacologiche “Mario Negri” IRCCS, Milan, Italy

²Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy

,

Nebojsa Mujovic

³School of Medicine, University of Belgrade, Belgrade, Serbia

⁴Cardiology Clinic, Clinical Centre of Serbia, University of Belgrade, Belgrade, Serbia

,

Tatjana S. Potpara

³School of Medicine, University of Belgrade, Belgrade, Serbia

⁴Cardiology Clinic, Clinical Centre of Serbia, University of Belgrade, Belgrade, Serbia

› Author Affiliations

Abstract

Full Text

References

References
1 Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost 2017; 117 (07) 1230-1239
2 Lip GY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?. Eur Heart J 2013; 34 (14) 1041-1049
3 Borre ED, Goode A, Raitz G. , et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost 2018 118. (12). Doi: 10.1055/s-0038-1675400
4 Lopes RD, Crowley MJ, Shah BR. , et al. Stroke Prevention in Atrial Fibrillation. Rockville, MD: Agency for Healthcare Research and Quality (US); 2013. . Report No.: 13-EHC113-EF. AHRQ Comparative Effectiveness Reviews.
5 Chen JY, Zhang AD, Lu HY, Guo J, Wang FF, Li ZC. CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis. J Geriatr Cardiol 2013; 10 (03) 258-266
6 Xiong Q, Chen S, Senoo K, Proietti M, Hong K, Lip GY. The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: a systemic review and meta-analysis. Int J Cardiol 2015; 195: 237-242
7 Zhu WG, Xiong QM, Hong K. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation. Tex Heart Inst J 2015; 42 (01) 6-15
8 Zhu W, Fu L, Ding Y. , et al. Meta-analysis of ATRIA versus CHA₂DS₂-VASc for predicting stroke and thromboembolism in patients with atrial fibrillation. Int J Cardiol 2017; 227: 436-442
9 Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012; 107 (06) 1172-1179
10 Potpara TS, Polovina MM, Licina MM, Marinkovic JM, Prostran MS, Lip GY. Reliable identification of “truly low” thromboembolic risk in patients initially diagnosed with “lone” atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol 2012; 5 (02) 319-326
11 Lip GYH, Banerjee A, Boriani G. , et al. Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report. Chest 2018; S0012-3692(18)32244-X
12 Lip GY, Laroche C, Popescu MI. , et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace 2015; 17: 1777-1786
13 Proietti M, Nobili A, Raparelli V, Napoleone L, Mannucci PM, Lip GY. ; REPOSI investigators. Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study. Clin Res Cardiol 2016; 105 (11) 912-920
14 Li CH, Liu CJ, Chou AY. , et al. European Society of Cardiology guideline-adherent antithrombotic treatment and risk of mortality in Asian patients with atrial fibrillation. Sci Rep 2016; 6: 30734
15 Mazurek M, Shantsila E, Lane DA, Wolff A, Proietti M, Lip GYH. Guideline-adherent antithrombotic treatment improves outcomes in patients with atrial fibrillation: insights from the Community-Based Darlington Atrial Fibrillation Registry. Mayo Clin Proc 2017; 92 (08) 1203-1213
16 Nielsen PB, Larsen TB, Skjøth F, Overvad TF, Lip GY. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study. Sci Rep 2016; 6: 27410
17 Olesen JB, Torp-Pedersen C. Stroke risk in atrial fibrillation: do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher?. Thromb Haemost 2015; 113 (06) 1165-1169
18 Fauchier L, Lecoq C, Clementy N. , et al. Oral anticoagulation and the risk of stroke or death in patients with atrial fibrillation and one additional stroke risk factor: the Loire Valley Atrial Fibrillation Project. Chest 2016; 149 (04) 960-968
19 Lip GY, Skjøth F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost 2015; 114 (04) 826-834
20 Potpara TS, Dagres N, Mujović N. , et al. Decision-making in clinical practice: oral anticoagulant therapy in patients with non-valvular atrial fibrillation and a single additional stroke risk factor. Adv Ther 2017; 34 (02) 357-377
21 Nielsen PB, Lip GY. Adding rigor to stroke rate investigations in patients with atrial fibrillation. Circulation 2017; 135 (03) 220-223
22 Nielsen PB, Skjøth F, Overvad TF, Larsen TB, Lip GYH. Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA₂DS₂-VA score rather than CHA₂DS₂-VASc?. Circulation 2018; 137 (08) 832-840
23 Brieger D, Amerena J, Attia J. , et al; NHFA CSANZ Atrial Fibrillation Guideline Working Group. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung Circ 2018; 27 (10) 1209-1266
24 Overvad TF, Potpara TS, Nielsen PB. Stroke risk stratification: CHA₂DS₂-VA or CHA₂DS₂-VASc?. Heart Lung Circ 2018; S1443-9506(18)31866-3
25 Maheshwari A, Norby FL, Roetker NS, et al. Refining prediction of atrial fibrillation-related stroke using the P₂-CHA₂DS₂-VASc score: The atherosclerosis risk in communities (ARIC) study and multi-ethnic study of atherosclerosis (MESA). Circulation 2018. Doi: 10.1161/CIRCULATIONAHA.118.035411
26 Steensig K, Olesen KKW, Thim T, et al. Should the presence or extent of coronary artery disease be quantified in the CHA₂DS₂-VASc score in atrial fibrillation? A report from the western Denmark heart registry. Thromb Haemost 2018. Doi: 10.1055/s-0038-1675401
27 Steensig K, Olesen KKW, Thim T. , et al. Coronary artery disease is independent risk factor for stroke among patients with atrial fibrillation. J Am Coll Cardiol 2018; S0735-1097(18)36961-4
28 Lip GY, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost 2016; 14 (09) 1711-1714
29 Esteve-Pastor MA, Rivera-Caravaca JM, Shantsila A, Roldán V, Lip GYH, Marín F. Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED score. The AMADEUS Trial. Thromb Haemost 2017; 117 (12) 2261-2266
30 Guo Y, Zhu H, Chen Y, Lip GYH. Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation. Am J Med 2018; 131 (02) 185-192
31 Chao TF, Lip GYH, Lin SL. , et al. Major bleeding and intracranial haemorrhage risk prediction in patients with atrial fibrillation: attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study. Int J Cardiol 2018; 254: 157-161
32 Chao TF, Lip GYH, Liu CJ. , et al. Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation. J Am Coll Cardiol 2018; 71 (02) 122-132
33 Chao TF, Lip GYH, Lin YJ. , et al. Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors. Thromb Haemost 2018; 118 (04) 768-777
34 Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017; 14 (11) 627-628